Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine

Vaccine

Volumn 31, Issue S4, 2013, Pages

  Schrag, Stephanie J ^a   Verani, Jennifer R ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Group B streptococcus; Intrapartum antibiotic prophylaxis; Maternal immunization; Neonatal sepsis

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN DERIVATIVE; STREPTOCOCCUS VACCINE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; GROUP B STREPTOCOCCAL INFECTION; GROUP B STREPTOCOCCAL MENINGITIS; GROUP B STREPTOCOCCAL PNEUMONIA; HUMAN; INFECTION PREVENTION; INTRAPARTUM CARE; MATERNAL MORBIDITY; MULTICENTER STUDY (TOPIC); PERINATAL INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; VACCINATION;

GROUP B STREPTOCOCCUS; INTRAPARTUM ANTIBIOTIC PROPHYLAXIS; MATERNAL IMMUNIZATION; NEONATAL SEPSIS;

AMPICILLIN; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PENICILLINS; PREGNANCY; PREMATURE BIRTH; PRENATAL DIAGNOSIS; REPRODUCTIVE TRACT INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; UNITED STATES;

EID: 84883021921     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.056     Document Type: Review

References (42)

1. Boyer K.M., Gotoff S.P. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986, 314(June (26)):1665-1669.
2. Tuppurainen N., Hallman M. Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients. Obstet Gynecol 1989, 73(April (4)):583-587.
3. Garland S.M., Fliegner J.R. Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis. Aust N Z J Obstet Gynaecol 1991, 31(2):119-122.
4. American Academy of Pediatrics Guidelines for prevention of group B streptococcal infection by chemoprophylaxis. Pediatrics 1992, 90:775-778.
5. Hankins G.V., Chalas E. Group B streptococcal infections in pregnancy: ACOG's recommendations. ACOG Newslett 1993, 37:2.
6. AAP Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics 1997, 99(March (3)):489-496.
7. ACOG ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173-June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 1996, 54(August (2)):197-205.
8. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recommendations and reports: morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 1996;45(RR-7)(May):1-24.
9. Schrag S.J., Zell E.R., Lynfield R., Roome A., Arnold K.E., Craig A.S., et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002, 347(July (4)):233-239.
10. ACOG ACOG Committee Opinion: number 279, December 2002. Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol 2002, 100(December (6)):1405-1412.
11. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recommendations and reports 2002;51(RR-11)(Aug):1-22.
12. Verani J.R., McGee L., Schrag S. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. Morb Mortal Wkly Rep 2010, 59(RR-10):1-32.
13. Castor M.L., Whitney C.G., Como-Sabetti K., Facklam R.R., Ferrieri P., Bartkus J.M., et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008, 2008:727505.
14. Allegaert K., van Mieghem T., Verbesselt R., de Hoon J., Rayyan M., Devlieger R., et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009, 200(February (2)). pp. 170 e1-e7.
15. Factor S.H., Whitney C.G., Zywicki S.S., Schuchat A. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. The active bacterial core surveillance team. Obstet Gynecol 2000, 95(March (3)):377-382.
16. Van Dyke M.K., Phares C.R., Lynfield R., Thomas A.R., Arnold K.E., Craig A.S., et al. Evaluation of universal antenatal screening for group B streptococcus. NEJM 2009 2009, 360(June (25)):2626-2636.
17. Pulver L.S., Hopfenbeck M.M., Young P.C., Stoddard G.J., Korgenski K., Daly J., et al. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol 2009, 29(January (1)):20-25.
18. Stoll B.J., Hansen N.I., Sanchez P.J., Faix R.G., Poindexter B.B., Van Meurs K.P., et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011, 127(May (5)):817-826.
19. Verani JR, Spina NL, Lynfield R, Schaffner W, Harrison LH, Holst A, et al. Potential for further reduction of early-onset group B streptococcal disease in neonates. ID Week 2012. San Diego, CA, 2012: poster #1647.
20. Jordan H.T., Farley M.M., Craig A., Mohle-Boetani J., Harrison L.H., Petit S., et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008, 27(December (12)):1057-1064.
21. Joseph T.A., Pyati S.P., Jacobs N. Neonatal early-onset Escherichia coli disease. The effect of intrapartum ampicillin. Arch Pediatr Adolesc Med 1998, 152(January (1)):35-40.
22. Mercer B.M., Carr T.L., Beazley D.D., Crouse D.T., Sibai B.M. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 1999, 181(October (4)):816-821.
23. Terrone D.A., Rinehart B.K., Einstein M.H., Britt L.B., Martin J.N., Perry K.G. Neonatal sepsis and death caused by resistant Escherichia coli: possible consequences of extended maternal ampicillin administration. Am J Obstet Gynecol 1999, 180(June (6) Pt 1):1345-1348.
24. Moore M.R., Schrag S.J., Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003, 3(April (4)):201-213.
25. Schrag S.J., Hadler J.L., Arnold K.E., Martell-Cleary P., Reingold A., Schuchat A. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics 2006, 118(August (2)):570-576.
26. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347(July (4)):240-247.
27. Stoll B.J., Hansen N.I., Higgins R.D., Fanaroff A.A., Duara S., Goldberg R., et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005, 24(July (7)):635-639.
28. Lukacs S.L., Schrag S.J. Clinical sepsis in neonates and young infants, United States, 1988-2006. J Pediatr 2012, 160(June (6)):960-9650.
29. Lin F.Y., Brenner R.A., Johnson Y.R., Azimi P.H., Philips J.B., Regan J.A., et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. Am J Obstet Gynecol 2001, 184(May (6)):10-1204.
30. Fairlie T, Zell ER, Schrag SJ. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. Obstetrics and Gynecology. 2013, in press.
31. Isaacs D., Royle J.A. Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia Australasian Study Group for Neonatal Infections. Pediatr Infect Dis J 1999, 18(June (6)):524-528.
32. Lopez Sastre J.B., Fernandez Colomer B., Coto Cotallo G.D., Ramos Aparicio A. Trends in the epidemiology of neonatal sepsis of vertical transmission in the era of group B streptococcal prevention. Acta Paediatr 2005, 94(April (4)):7-451.
33. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379(February (9815)):547-556.
34. Schrag S.J., Cutland C.L., Zell E.R., Kuwanda L., Buchmann E.J., Velaphi S.C., et al. Risk factors for neonatal sepsis and perinatal death among infants enrolled in the prevention of perinatal sepsis trial, Soweto, South Africa. Pediatr Infect Dis J 2012, 31(August (8)):821-826.
35. Phares C., Lynfield R., Farley M., Mohle-Boetani J., Harrison L., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299:2056-2065.
36. Centers for Disease Control and Prevention Influenza vaccination coverage among pregnant women-United States, 2010-11 influenza season. Morb Mortal Wkly Rep 2011, 60:1078-1082.
37. Goldenberg R.L., Thompson C. The infectious origins of stillbirth. Am J Obstet Gynecol 2003, 189(September (3)):861-873.
38. Turrentine M.A., Ramirez M.M. Recurrence of group B streptococci colonization in subsequent pregnancy. Obstet Gynecol 2008, 112(Augutst (2) Pt 1):259-264.
39. Hillier S, Ferris D, Fine D, Ferrieri P, Edwards MSC, V., Ewell M, et al. Women Receiving Group B Streptococcus Serotype III Tetanus Toxoid (GBS III-TT) Vaccine Have Reduced Vaginal and Rectal Acquisition of GBS Type III. Infectious Diseases Society of America Annual Meeting. Philadelphia, PA, 2009.
40. Seale A., Finn A. What is the best way to use conjugate vaccines?. Curr Opin Infect Dis 2011, 24(June (3)):219-224.
41. Dahesh S., Hensler M.E., Van Sorge N.M., Gertz R.E., Schrag S., Nizet V., et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 2008, 52(August (8)):2915-2918.
42. Kimura K., Suzuki S., Wachino J., Kurokawa H., Yamane K., Shibata N., et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008, 52(August (8)):2890-2897.